Clinical evidence for drug treatments in obesity-associated hypertensive patients - A discussion paper

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 27, Issue 2, 2005, Pages 119-125

  Doggrell, Sheila A ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Doggrell Biomedical Communications   (New Zealand)

Author keywords

Beta blockers; Calcium channel blockers; Centrally acting antihypertensives; Diuretics; Hypertension; Insulin sensitivity; Obesity; Orlistat; Sibutramine

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INSULIN; RENIN; RILMENIDINE; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ADRENERGIC SYSTEM; BODY WEIGHT; DISEASE ASSOCIATION; DRUG EFFECT; ESSENTIAL HYPERTENSION; EXTRACELLULAR SPACE; HEART OUTPUT; HEMODYNAMICS; HUMAN; HYPERTENSION; HYPERVOLEMIA; INSULIN SENSITIVITY; OBESITY; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; WEIGHT REDUCTION;

ANTI-OBESITY AGENTS; ANTIHYPERTENSIVE AGENTS; APPETITE DEPRESSANTS; CYCLOBUTANES; HUMANS; HYPERTENSION; INSULIN; LACTONES; LIPIDS; OBESITY;

EID: 17044437409     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.2005.27.2.876281     Document Type: Review

References (62)

1. MacMahon, S.-W., Blacket, R.-B., Macdonald, G.-J., Hall, W. Obesity, alcohol consumption and blood pressure in Australian men and women. The National Heart Foundation of Australia Risk Factor Prevalance Study. J Hypertens 1984, 2: 85-91.
2. Kannel, W.-B., Brand, N., Skinner, J.-J., Jr, Dawber, T.-R., McNamara, P.-M. The relation of adiposity to blood pressure and development of hypertension. The Framingham study. Ann Intern Med 1967, 67: 48-59.
3. Garrison, R.-J., Kannel, W.-B., Stokes, J, III, Castelli, W.-P. Incidence and precursors of hypertension in young adults: The Framingham Offspring Study. Prev Med 1987, 16: 235-52.
4. Stamler, R., Stamler, J., Riedlinger, W.-F., Algera, G., Roberts, R.-H. Weight and blood pressure. Findings in hypertension screening of 1 million Americans. JAMA 1978, 240: 1607-10.
5. Huang, Z., Willet, W.-C., Manson, J.-E. Body weight, weight change, and risk for hypertension in women. Ann Intern Med 1998, 128: 81-8.
6. Reisen, E., Abel, R., Modan, M. et al. Effect of weight loss without salt restriction on the reduction of blood pressure in overweight hypertensive patients. N Engl J Med 1978, 298: 1-6.
7. Stevens, V.-J.. Corrigan, S.-A., Obarzanek, E. et al. Weight loss intervention in phase 1 of the Trials of Hypertension Prevention. The TOHP Collaborative Research Group. Arch Intern Med 1993, 153: 849-58.
8. Kolanowski, J. Obesity and hypertension: from pathophysiology to treatment. Int J Obes Relat Metab Disord 1999, 23(Suppl 1): 42-6.
9. Hall, J.-E., Shek, E.W., Brands, M.W. Is leptin a link between obesity and hypertension? Curr Opin Endocrinol Diabetes 1999, 6: 225-9.
10. Zhang, R., Reisin, E. Obesity-hypertension: The effects on cardiovascular and renal systems. Am J Hypertens 2000, 13: 1308-14.
11. Kunz, I., Schorr, U., Klaus, S., Sharma, A.-M. Resting metabolic rate and substrate use in obesity hypertension. Hypertension 2000, 36: 26-32.
12. Hall, J.-E., Brands, M.-W., Henegar, J.-R. Mechanisms of hypertension and kidney disease in obesity. Ann NY Acad Sci 1999, 892: 91-107.
13. Manicardi, V., Camellini, L., Bellodi, G., Coscelli, C., Ferrannini, E. Evidence for an association of high blood pressure and hyperinsulinemia in obese men. J Clin Endocrinol Metab 1986, 62: 1302-4.
14. Sowers, J.-R., Whitfield, L.-A., Catania, R.-A. et al. Role of the sympathetic nervous system in blood pressure maintenance in obesity. J Clin Endocrinol Metab 1982, 54: 1181-6.
15. Rumantir, M.-S., Vaz, M., Jennings, G.-L. et al. Neural mechanisms in human obesity-related hypertension. J Hypertens 1999, 17: 1125-33.
16. Hall, J.-E. Mechanisms of abnormal renal sodium handling in obesity hypertension. Am J Hypertens 1997, 10: 49S-55S.
17. Grassi, G., Seravalle, G., Dell'Oro, R. et al. Adrenergic and reflex abnormalities in obesity-related hypertension. Hypertension 2000, 36: 538-42.
18. Sjostrom, L., Rissanen, A., Andersen, T. et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998, 352: 167-72.
19. Davidson, M.-H., Hauptman, J., DiGirolamo, M. et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: A randomized controlled trial. JAMA 1999, 281: 235-42.
20. Heymsfield, S.-B., Segal, K.-R., Hauptman, J. et al. Effects of weight loss with orlistat on glucose tolerance and progression of type 2 diabetes in obese adults. Arch Intern Med 2000, 160: 1321-6.
21. Broom, I., Wilding, J., Stott, P., Myers, N., UK Multimorbidity Study Group. Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study. Int J Clin Pract 2002, 56: 494-9.
22. Sharma, A.-M., Golay, A. Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patients with hypertension. J Hypertens 2002, 16: 5-11.
23. Bakris, G., Calhoun, D., Egan, B. et al. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. J Hypertens 2002, 20: 2257-67.
24. Birkenfeld, A.-L., Schroeder, C., Boschmann, M. et al. Paradoxical effect of sibutramine on autonomic cardiovascular regulation. Circulation 2002, 106: 2459-65.
25. James, W.-P., Astrup, A., Finer, N. et al. Effects of sibutramine on weight maintenance after weight loss: A randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000, 356: 2119-25.
26. McMahon, F.-G., Fujioka, K., Singh, B.-N. et al. Efficacy and safety of sibutramine in obese and African American patients with hypertension: A 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med 2000, 160: 2185-91.
27. McMahon, F.-G., Weinstein, S.-P., Rowe, E. et al. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. J Hum Hypertens 2002, 16: 4-11.
28. Sramek, J.-J., Leibowitz, M.-T., Weinstein, S.-P. et al. Efficacy and safety of sibutramine for weight loss in obese and hypertension well controlled by β-adrenergic blocking agents: A placebo-controlled, double-blind, randomized trial. J Human Hypertens 2002, 16: 13-19.
29. Fanghanel, G., Cortinas, L., Sanchez-Reyes, L. et al. Safety and efficacy of sibutramine in overweight Hispanic patients with hypertension. Adv Ther 2003, 20: 101-13.
30. Tambascia, M.-A., Geloneze, B., Repetto, E.-M. et al. Sibutramine enhances insulin sensitivity ameliorating metabolic parameters in a double-blind, randomized, placebo-controlled trial. Diabetes Obes Metab 2003, 5: 338-44.
31. Gokeel, A., Karakose, H, Ertorer, E.M. et al. Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. Diabetes Care 2001, 24: 1957-60.
32. Santucci, A., Ferri, C. Insulin resistance and essential hypertension: Pathophysiological and therapeutic implications. J Hypertens Suppl 1992, 10: S9-S15.
33. Passmore, A.P., Whitehead, E.M., Crawford, V., McVeigh, G.E., Johnstone, G.D. The antihypertensive and metabolic effects of low and conventional dose cyclopenthiazide in type II diabetics with hypertension. Q J Med 1991, 81: 919-28.
34. Curb, J.D., Pressep, S.L., Cutler, J.A. et al. Effect of diuretic-based antihypertensive treatment of cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 1996. 276: 1886-92.
35. Savage, P.J., Pressel, S.L., Curb, J.D. et al. Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated hypertension: The systolic hypertension in the Elderly Program. Arch Intern Med 1998, 158: 741-51.
36. Maccario, M., Oleandri, S.-E., Avogadri, E. et al. Effects of 3-month nifedipine treatment on endocrine-metabolic parameters in patients with abdominal obesity and mild hypertension. J Endocrinol Invest 1998, 21: 56-63.
37. Reisin, E., Weir, M.-R., Falkner, B. et al. Lisinopril versus hydrochlorothiazide in obese hypertensive patients. A multicenter placebo-controlled trial. Hypertension 1997, 30: 140-5.
38. Grassi, G., Seravalle, G., Dell'Oro, R. et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: Results of the CROSS study. J Hypertens 2003, 21: 1761-9.
39. Bohlen, L., Bienz, R., Doser, M. et al. Metabolic neutrality of perindopril: Focus on insulin sensitivity in overweight patients with essential hypertension. J Cardiovasc Pharmacol 1996, 27: 770-6.
40. Cabezas-Cerrato, J., Garcia-Estevez, D.-A., Araujo, D., Iglesias, M. Insulin sensitivity, glucose effectiveness, and beta-cell function in obese males with essential hypertension: Investigation of the effects of treatment with a calcium channel blacker (diltiazem) or an angiotensin-converting enzyme inhibitor (quinapril). Metabolism 1997, 46: 173-8.
41. Galletti, F., Strazzullo, P., Capaldo, B. et al. Controlled study of the effect of angiotensin convening enzyme inhibition versus calcium-entry blockade on insulin sensitivity in overweight hypertensive patients: Trandolapril Italian Study (TRIS). J Hypertens 1999, 17: 439-45.
42. Shiuchi, T., Cui, T.-X., Wu, L. et al. ACE inhibitor improves insulin resistance in diabetic mouse via bradykinin and NO. Hypertension 2002, 40: 329-34.
43. Duka, I., Shenouda, S., Johns, C. et al. Role of the B(2) receptor of bradykinin in insulin sensitivity. Hypertension 2001, 38: 1355-60.
44. Henriksen, E.-J., Jacob, S., Fogt, D.-L., Dietze, G.-J. Effect of chronic bradykinin administration on insulin action: An animal model of insulin resistance. Am J Physiol 1998, 275: R40-R45.
45. Fogari, R., Zoppi, A., Lazzari, P. et al. ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients. J Cardiovasc Pharmacol 1998, 32: 616-20.
46. Greiss, -T.-W., Nieto, F.-J., Shahar, E. et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N. Engl J Med 2000, 342: 905-12.
47. Morel, Y., Gradient, A., Keller, U., Vadas, L., Golay, A. Insulin sensitivity in obese hypertensive dyslipidemic patients treated with enalapril or atenolol. J Cardiovasc Pharmacol 1995, 26: 306-11.
48. Utrianen, T., Takala, T., Luotolahti, M. et al. Insulin resistance characterized glucose uptake in skeletal muscle but not in the heart in NIDDM. Diabetologia 1998, 41: 555-9.
49. Kuperstein, R., Sasson, Z. Effects of antihypertensive therapy on glucose and insulin metabolism and on left ventricular mass: A randomized, double-blind, controlled study of 21 obese hypertensives. Circulation 2000, 102: 1802-6.
50. Bonner, G., Schmieder, R., Chrosch, R., Weisinger, G. Effect of bunazosin and atenolol on glucose metabolism in obese nondiabetic patients with primary hypertension. Cardiovasc Drugs Ther 1997, 11: 21-6.
51. De Luca, N., Izzo, R., Fontana, D. et al. Haemodynamic and metabolic effects of rilmenidine in hypertensive patients with metabolic syndrome X. A double-blind parallel study versus amlodipine. J Hypertens 2000, 18: 1515-22.
52. Fogari, R., Zoppi, A., Tettamanti, F. et al. beta-Blocker effects on plasma lipids in antihypertensive therapy: Importance of the duration of treatment and the lipid status before treatment. J Cardiovasc Pharmacol 1990, 16(Suppl 5): S76-S80.
53. Lakshman, M.-R., Reda, D.-J., Materson, B.-J., Cushman, W.-C., Freis, E.-D. Diuretics and beta-blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Arch Intern Med 1999, 159: 551-8.
54. Reisin, E., Weed, S.-G. The treatment of obese hypertensive black women: A comparative study of chlorthalidone versus clonidine. J Hypertens 1992, 10: 489-93.
55. Chrysant, G.S, Chrysant, S.O. Has the role of calcium channel blockers in treating hypertension finally been defined? Curr Hypertens Rep 2003, 5: 295-300.
56. Pischon, T., Sharma, A.-M. Use of beta-blockers in obesity hypertension: Potential role of weight gain. Obese Rev 2001, 2: 275-80.
57. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomised to doxazosin vs chlorthalidone: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000, 283: 1967-75.
58. Wofford, M.-R., Anderson, D.-C., Jr, Brown, C.-A. et al. Antihypertensive effect of α- and beta-adrenergic blockade in obese and lean hypertensive subjects. Am J Hypertens 2001, 14: 694-8.
59. Guigliano, D, Acampora, R, Marfella, R. et al. Hemodynamic and metabolic effects of transdermal clinidine in patients with hypertension and non-insulin-dependent diabetes mellitus. Am J Hypertens 1998, 11: 184-9.
60. Rocchini, A.P, Mao, H.Z, Babu K, Marker P, Rocchini, A.J. Clonidine prevent insulin resistance and hypertension in obese dogs. Hypertension 1999, 33: 548-53.
61. Doggrell, S.A. Angiotensin AT-1 receptor antagonism: Complementary or alternative to ACE inhibition in cardiovascular and renal disease. Expert Opin Pharmacotherapy 2002, 3: 1543-56.
62. Higueruelo, S., Vaquera, M., Pastor, C., Galimany, R., Romero, R. Fosinopril ameliorates exogenous cholesterol-induced incipient glomerular lesions in obese Zucker rats. Effects on eicosanoids. Nephrol Dial Transplant 1998, 13:2227-33.